Abstract
<div>Abstract<p><b>Purpose:</b> Activating <i>ALK</i> mutations are present in almost 10% of primary neuroblastomas and mark patients for treatment with small-molecule ALK inhibitors in clinical trials. However, recent studies have shown that multiple mechanisms drive resistance to these molecular therapies. We anticipated that detailed mapping of the oncogenic ALK-driven signaling in neuroblastoma can aid to identify potential fragile nodes as additional targets for combination therapies.</p><p><b>Experimental Design:</b> To achieve this goal, transcriptome profiling was performed in neuroblastoma cell lines with the <i>ALK<sup>F1174L</sup></i> or <i>ALK<sup>R1275Q</sup></i> hotspot mutations, <i>ALK</i> amplification, or wild-type <i>ALK</i> following pharmacologic inhibition of ALK using four different compounds. Next, we performed cross-species genomic analyses to identify commonly transcriptionally perturbed genes in <i>MYCN/ALK<sup>F1174L</sup></i> double transgenic versus <i>MYCN</i> transgenic mouse tumors as compared with the mutant ALK-driven transcriptome in human neuroblastomas.</p><p><b>Results:</b> A 77-gene ALK signature was established and successfully validated in primary neuroblastoma samples, in a neuroblastoma cell line with <i>ALK<sup>F1174L</sup></i> and <i>ALK<sup>R1275Q</sup></i> regulable overexpression constructs and in other ALKomas. In addition to the previously established PI3K/AKT/mTOR, MAPK/ERK, and MYC/MYCN signaling branches, we identified that mutant ALK drives a strong upregulation of MAPK negative feedback regulators and upregulates RET and RET-driven sympathetic neuronal markers of the cholinergic lineage.</p><p><b>Conclusions:</b> We provide important novel insights into the transcriptional consequences and the complexity of mutant ALK signaling in this aggressive pediatric tumor. The negative feedback loop of MAPK pathway inhibitors may affect novel ALK inhibition therapies, whereas mutant ALK induced RET signaling can offer novel opportunities for testing ALK-RET oriented molecular combination therapies. <i>Clin Cancer Res; 21(14); 3327–39. ©2015 AACR</i>.</p></div>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
